Brazil confirms first bird flu outbreak in commercial poultry
SAO PAULO — Brazil's Ministry of Agriculture and Livestock on Friday confirmed the country's first bird flu outbreak in a commercial poultry.
The virus was found at a facility in the southern state of Rio Grande do Sul, the ministry said in a statement. It added it has begun implementing a contingency plan 'not only to eliminate the disease but also to maintain the sector's productive capacity, ensuring supply and, consequently, food security for the population.'
The ministry added that it has also notified the World Organization for Animal Health, the Ministries of Health and the Environment and Brazil's trade partners.
Agriculture and Livestock minister Carlos Fávaro said Friday that China has halted poultry imports from Brazil for 60 days, according to local media.
The ministry also said the disease is not transmitted through the consumption of poultry meat or eggs.
'The risk of human infection by the avian flu virus is low and occurs mostly among handlers or professionals who have close contact with infected birds (alive or dead),' the ministry said.
____
Follow AP's coverage of Latin America and the Caribbean at https://apnews.com/hub/latin-america
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
26 minutes ago
- Bloomberg
EU Poised to Curb China's Access to Medical Device Procurement
The European Union is set to curb Chinese medical device manufacturers' access to public procurement contracts in the bloc, according to a person familiar with the matter. EU countries are due to vote on the proposed measure as early as Monday, said the person, who spoke on condition of anonymity to discuss private deliberations.
Yahoo
6 hours ago
- Yahoo
China robotaxis, Indian pharma among hedge fund top picks at Sohn Hong Kong
By Summer Zhen HONG KONG (Reuters) -Hedge funds revealed their top investment ideas, ranging from Chinese self-driving taxis, an Indian drug retailer, to a Korean nuclear plant builder, at the annual Sohn investment conference in Hong Kong. This year's picks are geographically more diverse compared to last year, suggesting that investors are actively seeking to spread their exposure to counter tariff uncertainties and market volatility. San Francisco-based Flight Deck Capital sees upside potential in Chinese search engine giant Baidu, betting on its fast-growing auto-driving business. Similar to Google's self-driving unit Waymo, Baidu's Apollo Go "is the only robo-taxi player in China that's not dependent on the capital markets to scale," Flight Deck founder and managing partner Jay Kahn said at the conference on Friday. He expects China's taxi and ride-share industry to grow to around $237 billion by 2034, with Apollo taking a 15% market share. But that segment, together with Baidu's cloud business, is currently given zero valuation by the market, he said. Notably, investor optimism on Chinese firms going overseas has not been derailed by the escalating U.S.-China trade war. Hong Kong's Apeiron Capital pitched Chinese ride-hailing company DiDi Global, citing its improving margin at home and its quick market share building in Latin America. Meanwhile Triata Capital is upbeat on Chinese discount e-commerce player PDD, the owner of Temu. "One statistic that a lot of people don't know is that their MAU right now is bigger than Amazon," Triata CIO Sean Ho said, referring to Temu's monthly active users. INDIA Two investors set their sights on India's healthcare space. Singapore's Arisaig Partners favors MedPlus Health Services, a leading pharmacy chain in India, as its private label products strengthen its low-price proposition, widening the gap with competitors. "Inflation is lower, government is focusing on the middle class and consumer spending is coming off a low base. I simply believe this is the time when the consumer space in general will do better," Vatsal Mody, partner and head of India research at Arisaig Partners said in an interview ahead of the conference. India-based hedge fund startup Panvira Management is bullish on Piramal Pharma, a contract development and manufacturing organisation (CDMO), expecting its growth to accelerate to high teens and to benefit from tax rate normalisation. SECURITY AND ACTIVISTS Other emerging hedge funds focused on opportunities in the security sector driven by geopolitical conflicts. Jon Jhun, who manages Management's new Korea-focused fund, chose Hyundai Engineering & Construction, which engages in nuclear plant engineering, procurement and construction (EPC). "Korea dominates the ex-Russia, ex-China nuclear supply chain," he said. Hong Kong's Frontline Global Management picked Spanish defence firm Indra Sistemas, believing the firm will win more European contracts. On the activist investor side, UK hedge fund Palliser Capital disclosed a 3% stake in Japan's Toyo Tire at the event, urging the tire maker to boost shareholder returns by setting a "best-in-class" performance target and releasing its excess capital of about $900 million to shareholders. Seth Fischer's Oasis Management is long Japanese entertainment complex chain Round One, betting it will gain a re-rating as it ventures into the restaurant industry aiming to bring Michelin-quality Japanese food to the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
7 hours ago
- Associated Press
Latest Data of InnoCare's Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
BEIJING--(BUSINESS WIRE)--Jun 1, 2025-- Latest data of InnoCare's robust oncology pipelines were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Oral Presentation Title: Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL) (Abstract No.: 2514) The current study is the first and only report on the preliminary efficacy data of anti-CCR8 targeted therapy for CTCL patients. The efficacy of ICP-B05 was supported by the PD effects in both skin lesions and peripheral blood in the depletion of CCR8+ cells. ICP-B05 is safe and well tolerated and its safety profile made it a good candidate for combo therapies for CTCL patients with lymph node and other organ involvement. As of Jan. 6, 2025, a total of 13 patients with R/R CTCL were treated. There were 12 patients received at least one skin lesion assessment followed the mSWAT. 33.3% of patients achieved PR, and 58.3% of patients were assessed as SD with reduction in skin lesion. The 6-month PFS rate was 82.5%, and the median PFS was 11.4 months. Among the five patients with CCR8+ levels exceeding 10%, four (80%) achieved PR. PK analysis showed that serum exposure (Cmax and AUC0-14D) increased with dose escalation. PD analysis demonstrated significant depletion of CCR8-expressing cells in CTCL skin lesions. Poster 1: Title: Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies (Abstract No.: 7038) The results of ICP-248 monotherapy suggests a well-tolerated safety profile and an exciting efficacy in BTK failed, heavily treated, relapsed or refractory B-cell malignancies. As of April 15, 2025, a total of 68 patients were enrolled in the dose escalation and dose expansion study. 17 R/R CLL/SLL and 32 R/R MCL patients were treated with 125 mg of ICP-248, including 10 CLL/SLL and 25 MCL patients were previously treated with BTK inhibitors, and 70.0% of CLL/SLL patients and 100% of MCL patients were resistant to BTK inhibitors. 17 CLL/SLL and 26 MCL patients had at least one response assessment. Among the BTK naïve patients, the ORR for R/R CLL/SLL and R/R MCL patients were both 100%, and the CRR was 14.3% and 71.4% respectively, of which 43% of MCL patients reported undetectable minimal residual disease (uMRD). Among the BTK treated patients, the ORR for R/R CLL/SLL and R/R MCL patients were 100% and 78.9% respectively, and the CRR were 30.0% and 26.3% respectively, of which uMRD was reported in 20% of CLL/SLL and 16% of MCL patients. The median PFS of R/R MCL patients who had received treatment of BTK inhibitors before was 8.3 months. The PFS was not reached among BTK naïve R/R CLL/SLL and R/R MCL patients and BTK-treated R/R CLL/SLL patients. Poster 2: Title: Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients with NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 10048) The integrated analysis demonstrated that zurletrectinib had significant efficacy and good safety profile in pediatric and adolescent patients with NTRK+ solid tumors. Zurletrectinib also showed the potential to overcome the resistance to first generation TRK inhibitors. These findings support zurletrectinib is a better treatment option for NTRK+ pediatric and adolescent patients. As of Nov. 23, 2024, 18 patients in total were enrolled, including 8 pediatric patients and 10 adolescent patients. Among the 18 patients, 6 TRK inhibitor treatment-naïve patients with central lab confirmed NTRK+ were efficacy evaluable. The confirmed ORR assessed by IRC was 100%. All patients achieved partial response (PR) at the first tumor assessment and maintained the remission as of the cutoff date. Median time to response were 1.0 month in adolescent patients and 0.9 month in pediatric patients. It is worth noting that one pediatric patient who progressed on prior first-generation TRK inhibitor achieved complete response after receiving zurletrectinib. Poster 3: Title: Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 3112) In line with previously reported results, zurletrectinib continued to demonstrate a deep and durable responses in adult patients with NTRK+ advanced solid tumors with or without brain metastasis. Zurletrectinib was also well-tolerated and showed favorable safety profile in adult patients with various tumor types. As of Nov. 23, 2024, a total of 49 TRK inhibitor naïve adult patients were evaluable for efficacy representing 12 different solid tumor types. Among the efficacy population, the distribution of NTRK1, NTRK2 and NTRK3 fusions was 53.1%, 2.0% and 44.9% respectively. The confirmed ORR by IRC was 83.7%, with CR of 10.2%. Median duration of response (DOR) and median progression-free survival (PFS) by IRC were not reached. The DOR rate and PFS rate by IRC at 12 months was 92.0% and 90.5% respectively. Two of the three patients who had brain metastasis at the baseline achieved intracerebral ORR, which is consistent with the good brain penetration and strong intracranial activity of zurletrectinib. The 2025 ASCO Annual Meeting is held from May 30 to June 3, 2025 in Chicago, U.S. The ASCO annual meeting is the most important and professional academic event in the global oncology field, which showcases the international cutting-edge clinical oncology research results and tumor treatment technologies. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View source version on CONTACT: Media Chunhua Lu 86-10-66609879 [email protected] 86-10-66609999 [email protected] KEYWORD: CHINA ASIA PACIFIC INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS SOURCE: InnoCare Pharma Copyright Business Wire 2025. PUB: 06/01/2025 08:30 PM/DISC: 06/01/2025 08:31 PM
